Literature DB >> 11486902

Factor V Leiden mutation in Turkish patients with homozygous cystathionine beta-synthase deficiency.

H S Kalkanoğlu1, T Coşkun, S D Aydoğdu, A Tokatli, A Gürgey.   

Abstract

Venous and arterial thromboembolism can occur in patients with homocystinuria. Resistance to activated protein C, which is caused by a single point mutation in the gene for factor V, renders an individual at risk for thrombosis. It has been suggested that coexistence of hereditary homocystinuria and factor V Leiden mutation might jointly play a role in the development of thrombosis. We analysed six patients with homocystinuria due to cystathionine beta-synthase deficiency for factor V Leiden and prothrombin G20210A mutations. Only one patient was found to have the factor V Leiden mutation in homozygous form and this patient had suffered from severe thrombosis. One patient was found to be heterozygous with no documented thrombosis. None of the patients had prothrombin G20210A mutation. We stress the necessity for screening for known thrombophilic risk factors in patients with cystathonine beta-synthase deficiency. The coexistence of the factor V Leiden mutation can cause severe thrombotic events in patients with homocystinuria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11486902     DOI: 10.1023/a:1010556603183

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  9 in total

1.  The prevalence of factor V Leiden (1691 G-->A) mutation in Turkey.

Authors:  A Gürgey; L Mesci
Journal:  Turk J Pediatr       Date:  1997 Jul-Sep       Impact factor: 0.552

2.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.

Authors:  S R Poort; F R Rosendaal; P H Reitsma; R M Bertina
Journal:  Blood       Date:  1996-11-15       Impact factor: 22.113

Review 3.  Homocysteine and atherothrombosis.

Authors:  G N Welch; J Loscalzo
Journal:  N Engl J Med       Date:  1998-04-09       Impact factor: 91.245

4.  Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency.

Authors:  S Yap; K A O'Donnell; C O'Neill; P D Mayne; P Thornton; E Naughten
Journal:  Thromb Haemost       Date:  1999-04       Impact factor: 5.249

Review 5.  Activated protein C resistance--a major risk factor for thrombosis.

Authors:  S B Rosén; A Sturk
Journal:  Eur J Clin Chem Clin Biochem       Date:  1997-07

6.  Factor V Q 506 mutation in children with thrombosis.

Authors:  A Gurgey; L Mesci; Y Renda; L Olcay; N Kocak; G Erdem
Journal:  Am J Hematol       Date:  1996-09       Impact factor: 10.047

7.  Mutation in blood coagulation factor V associated with resistance to activated protein C.

Authors:  R M Bertina; B P Koeleman; T Koster; F R Rosendaal; R J Dirven; H de Ronde; P A van der Velden; P H Reitsma
Journal:  Nature       Date:  1994-05-05       Impact factor: 49.962

8.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.

Authors:  B Dahlbäck; M Carlsson; P J Svensson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

9.  Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis.

Authors:  H Mandel; B Brenner; M Berant; N Rosenberg; N Lanir; C Jakobs; B Fowler; U Seligsohn
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

  9 in total
  1 in total

1.  Severe hyperhomocysteinemia due to cystathionine β-synthase deficiency, and Factor V Leiden mutation in a patient with recurrent venous thrombosis.

Authors:  Zuhier Awan; Sumayah Aljenedil; David S Rosenblatt; Jean Cusson; Brian M Gilfix; Jacques Genest
Journal:  Thromb J       Date:  2014-12-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.